ERIC BOERWINKLE to Calcium Channel Blockers
This is a "connection" page, showing publications ERIC BOERWINKLE has written about Calcium Channel Blockers.
Connection Strength
0.220
-
NOS1AP variant associated with incidence of type 2 diabetes in calcium channel blocker users in the Atherosclerosis Risk in Communities (ARIC) study. Diabetologia. 2010 Mar; 53(3):510-6.
Score: 0.075
-
Genetic Variants Associated With Uncontrolled Blood Pressure on?Thiazide Diuretic/?-Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses)?and INVEST (International Verapamil-SR Trandolapril Study) Trials. J Am Heart Assoc. 2017 Nov 02; 6(11).
Score: 0.033
-
The effects of genes implicated in cardiovascular disease on blood pressure response to treatment among treatment-naive hypertensive African Americans in the GenHAT study. J Hum Hypertens. 2016 09; 30(9):549-54.
Score: 0.029
-
G protein receptor kinase 4 polymorphisms: ?-blocker pharmacogenetics and treatment-related outcomes in hypertension. Hypertension. 2012 Oct; 60(4):957-64.
Score: 0.023
-
RYR3 gene polymorphisms and cardiovascular disease outcomes in the context of antihypertensive treatment. Pharmacogenomics J. 2013 Aug; 13(4):330-4.
Score: 0.022
-
Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study. J Hypertens. 2010 Oct; 28(10):2076-83.
Score: 0.020
-
Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study. Pharmacogenet Genomics. 2009 Jun; 19(6):415-21.
Score: 0.018